

ISCT ANZ 2023 REGIONAL MEETING PROGRAM

16th – 18th August 2023 • Perth, Australia

Perth Convention & Exhibition Centre
Meeting Rooms 1, 2, 3 & 4



Tag **@ISCTGlobal** and
#ISCTANZ2023

Conference program

08:00 - 08:45	DAY 1, August 16, 2023 Registrations open		
08:45	OPENING		
			
	A/Prof Zlatibor Veličković ISCT Vice President, ANZ	Betty Garlett Whadjuk Noongar Elder Welcome to the Country	Hon Stephen Dawson Minister for Emergency Services, Innovation and the Digital, Economy, Science and Medical Research
Session 1: Plenary			
Chairs: A/Prof Zlatibor Veličković & A/Prof Emily Blyth			
			
09:15		Prof Jacques Galipeau President, International Society for Cell & Gene Therapy Don and Marilyn Anderson Professor in Oncology, Associate Dean for Therapeutics Development University of Wisconsin School of Medicine and Public Health, Director, UW Program for Advanced Cell Therapy, University of Wisconsin in Madison, USA Title: A roadmap towards risk-adapted regulatory approval schemes for sustainable access to personalised CGTs	
09:45		Prof Marina Cavazzana Biotherapy Department, Necker-Enfants Malades Hospital, AP-HP, Paris, France; Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Centre, AP-HP, INSERM, Paris, France; Imagine Institute, Université Paris Cité, Paris, France. The Geoff Symonds Oration: The coming of age of gene therapies	
10:15	Q&A		
10:30 - 10:50	Morning break with the Exhibitors Sponsored by Gilead		
			

Session 2: ISCT ANZ – ASSCR Joint Session

Chairs: Dr Jennifer Hollands & A/Prof Ngaire Elwood



10:50	 <p>A/Prof Pritinder Kaur Associate Professor Head Epithelial Stem Cell Biology Group School of Biomedical Sciences Curtin University, Curtin Health and Innovation Research Institute, Perth, Australia</p> <p>Title: Approaches to improve human skin regeneration</p>
11:15	Q&A
11:20	 <p>Dr Anai Gonzalez Cordero AI & Val Rosenstrauss Fellow, Stem Cell Medicine Group Leader, Children's Medical Research Institute, Westmead, Sydney, Australia</p> <p>Title: Developing cell replacement therapy for inherited retinal diseases</p>
11:45	Q&A
11:50	<p><i>Oral Abstract Presentation</i></p> <p>Pei Tian Murdoch Children's Research Institute, Melbourne, Australia</p> <p>Title: Creating clinically compliant induced pluripotent stem cell (iPSC) lines: transition from the research lab to full GMP</p>
12:00	Q&A
12:05	<p><i>Oral Abstract Presentation</i></p> <p>Dr Lisa Holmes Cell & Tissue Therapies WA, Royal Perth Hospital, Perth, Australia</p> <p>Title: Translating Research into Clinical Trial: Culturing Human Corneal Endothelial Cells for Corneal Endothelial Cell Injection Therapy</p>
12:15	Q&A
12:20 - 13:20	<p>Corporate Lunch Session Sponsored by Genscript ProBio</p> <p>Dr Yuyuan Dai Head of AP&EU Solution BD GenScript ProBio</p> <p>Title: mRNA One-stop Solution: Plasmid, Linearized DNA, IVT-mRNA and mRNA-LNP</p>  

Session 3: Preclinical Research

Chairs: Dr Guy Klamer & Dr Wei Jiang



13:20	 <p>Prof Jonas Nilsson Harry Perkins Institute of Medical Research, University of Western Australia, Perth, Australia; Sahlgrenska Center for Cancer Research, Dept of Surgery, University of Gothenburg, Sweden.</p> <p>Title: Defining tumor reactive lymphocytes in melanoma to improve cell therapy</p>
13:45	Q&A
13:50	 <p>A/Prof Misty Jenkins Laboratory Head, Immunology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.</p> <p>Title: Developing a novel pipeline for the preclinical testing of immunotherapy for brain cancer</p>
14:15	Q&A
14:20	<p><i>Oral Abstract Presentation</i></p> <p>Xiang Li Cancer Research, QIMR Berghofer Medical Research Institute, Brisbane, Australia</p> <p>Title: 4-1BB versus CD28 co-stimulation – tailored signalling for Glioblastoma-targeted CARs</p>
14:30	Q&A
14:35	<p><i>Oral Abstract Presentation</i></p> <p>Dr Ishmael Inocencio The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Australia</p> <p>Title: Testing the Preclinical Safety of Human Amniotic Epithelial Cell Derived Extracellular Vesicles in a Large Animal Model of Fetal Inflammation</p>
14:45	Q&A
14:50 - 15:10	<p>Afternoon break with the Exhibitors Sponsored by Gilead</p> 

Session 4: Process Development & Manufacturing

Chairs: Dr Rebecca Lim & Leon Brownrigg



15:10	 Dr Louise Smith Tekcyte Adelaide, Australia	 Harsha Gupta Cynata Therapeutics Limited, Melbourne, Australia	 Anna Ng Cell & Tissue Therapies WA, Perth, Australia		
Title: Developing an iPSC derived MSC therapy for Diabetic Foot Ulcers in Australia					
15:35	Q&A				
15:40	 A/Prof Leszek Lisowski Unit Head, Translational Vectorology Unit, Children's Medical Research Institute, Westmead, Sydney, Australia	Title: Novel bioengineered AAVs for gene therapy applications: how to make them and how to produce them!			
16:05	Q&A				
16:10	Oral Abstract Presentation Katherine Audsley PhD Candidate, Telethon Kids Institute, The University of Western Australia, School of Biomedical Sciences, University of Western Australia, Perth, Australia				
16:20	Title: Identifying novel therapeutic targets to improve adoptive cell therapy using a model of Flt3L-mediated tumor suppression				
16:25	Oral Abstract Presentation Dr Christina Scheffler Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia				
16:35	Title: Improving CAR T cell efficacy through the dual application of the PH inhibitor CellPryme				
16:40 – 19:00	Poster Viewing and Networking Event Sponsored by the Government of Western Australia				
19:30	Early Stage Professionals Social Sponsored by ISCT ANZ Executive Committee				



GOVERNMENT OF
WESTERN AUSTRALIA



CYTOTHERAPY[®]

THE OFFICIAL JOURNAL OF ISCT[®] INTERNATIONAL SOCIETY FOR CELL & GENE THERAPY

TAKE YOUR RESEARCH TO THE NEXT LEVEL

Publish With the Largest Global CGT Translation Society



Patrick Hanley, PhD

Cytotherapy Commissioning Editor

Cytotherapy provides an excellent platform to disseminate your research to our global translation readership.

Email me to discuss your interest in publishing and join many of your ANZ colleagues in a future issue of the Journal
(commish@isct-cytotherapy.org)

SUBMIT TODAY
WWW.ISCT-CYTOTHERAPY.ORG

International Society
ISCT 
Cell & Gene Therapy[®]

08:00 - 09:00		DAY 2, August 17, 2023 Registrations continue	
<div>Session 5: Regulatory Updates</div> <div>Chairs: Dr Gabrielle O’Sullivan & Craig Wright</div> <div><div></div><div></div></div>			
09:00	<div></div>	<div>Dr Glenn Smith</div> <div>Director Biological Science Section, Therapeutic Goods Administration (TGA), Canberra, Australia</div> <div>Title: Regulation of cell and tissue therapies, an update</div>	
09:15	Q&A		
09:20	<div></div>	<div>Dr Sarita Dhouchak</div> <div>Assistant Director, Office of the Gene Technology Regulator (OGTR), Canberra, Australia</div> <div>Title: An update on the regulation of human clinical trials with GMOs</div>	
09:35	Q&A		
09:40	<div></div>	<div>Dr Tim Strabala</div> <div>Principal Scientist, New Organisms, Hazardous Substances and New Organisms, Environmental Protection Authority (EPA) NZ, Wellington, New Zealand</div> <div>Title: Current GMO and biotechnology regulation in New Zealand</div>	
09:55	Q&A		
10:00	<div></div>	<div>Prof Phyllis Warkentin</div> <div>Chief Medical Officer, Foundation for the Accreditation of Cellular Therapy (FACT), Professor of Pathology /Microbiology and Pediatrics University of Nebraska Medical Center Omaha, NE, USA</div> <div>Title: The role of voluntary accreditation in cellular therapy: an update from FACT</div>	
10:15	Q&A		
10:20	Morning break with the Exhibitors Sponsored by Gilead		<div></div>
<div>Session 6: “Ask the Regulator” Scenarios Q&A</div> <div>Chairs: A/Prof Dominic Wall & Kasey Kime</div> <div><div></div><div></div></div>			
10:40	Panel discussion with the regulators (TGA, OGTR, EPA NZ and FACT)		

<p>12:00 - 13:00</p>	<div> <div>Corporate Lunch Session Sponsored by Rapidmicro</div> <div>  </div> <div>  </div> </div> <p>David Franken Business Manager AUSTRALIA Rapid Micro Biosystems (Melbourne)</p> <p>Title: Ensuring product safety when it really 'counts'</p>
	<div> <div>Session 7: Early Stage Professionals</div> <div>    </div> </div> <p>Introduction by Prof Jacques Galipeau ISCT President</p> <p>Chairs: Dr Madison Paton & Jessica Sue</p>
<p>13:10</p>	<p><i>Oral Abstract Presentation</i></p> <p>Dr Alicia Didsbury Research Fellow, Dunbar Lab, School of Biological Sciences, Te Kura Mātauranga Koiora, University of Auckland, Waipapa Taumata Rau, Auckland, Aotearoa, New Zealand</p> <p>Title: Facing The Challenges in Developing Immunotherapy for Ovarian Cancer in Resource-Limited Settings: Perspectives of an Early Career Researcher</p>
<p>11:18</p>	<p>Q&A</p>
<p>13:20</p>	<p><i>Oral Abstract Presentation</i></p> <p>Hannah Newnes PhD Candidate, Telethon Kids Institute, The University of Western Australia, School of Biomedical Sciences, University of Western Australia, Perth, Australia</p> <p>Title: Interrogating the functional diversity of type I interferons to generate tailored cellular therapies for cancer</p>
<p>13:28</p>	<p>Q&A</p>
<p>13:30</p>	<p><i>Oral Abstract Presentation</i></p> <p>Naveen Kumar PhD Candidate, The Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Australia</p> <p>Title: Testing the Feasibility of Immortalised Human Amniotic Epithelial Derived Extracellular Vesicles in a Rodent Model of Bronchopulmonary Dysplasia</p>
<p>13:38</p>	<p>Q&A</p>
<p>13:40</p>	<div>     </div> <p>Prof Dominic Wall A/Prof Ngaire Elwood Dr Janet Macpherson Dr Rebecca Lim</p> <p>Mentoring Panel Discussion</p>

14:30	Afternoon break with the Exhibitors Supported by Gilead		
Session 8: Gene Therapies			
Chairs: Dr Cheryl Hutchins and Prof Rajiv Khanna		 	
14:50		Dr Livia Carvalho Lions Eye institute, Perth, Australia Title: Developing a novel gene therapy for rare inherited blindness	
15:10	Q&A		
15:15		Prof Michelle Farrar Professor of Paediatric Neurology at the University of New South Wales, Specialist neurologist at Sydney Children's Hospital, Sydney, Australia Title: Treating spinal muscular atrophy	
15:35	Q&A		
15:40		Prof Robyn Jamieson Eye Genetics Research Unit Head, Children's Medical Research Institute, Head of the Western Sydney Genetics Program, The Children's Hospital at Westmead and Head, Speciality of Genomic Medicine, University of Sydney, Sydney Australia Title: Retinal gene therapy: implementation, outcomes and new horizons	
16:00	Q&A		
16:05	Oral Abstract Presentation John Hunt PhD Candidate, The University of Auckland, Auckland, New Zealand Title: Therapeutic genome editing for severe monogenic skin disorders		
16:15	Q&A		
16:17	Oral Abstract Presentation Ahmad Hammoud PhD Candidate, Centre for Heart Research, The Westmead Institute for Medical Research, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia Identifying Human Adeno-associated Virus Capsids for Cardiac Gene Therapy		
16:27	Q&A		

Session 9: Workforce Development

Introduction by Prof Jacques Galipeau ISCT President



Chairs: A/Prof Zlatibor Veličković & Dr Jennifer Hollands

16:30	 A/Prof Zlatibor Veličković Facility Director, Cell & Tissue Therapies WA, Royal Perth Hospital, Perth, Australia Title: ISCT Global Workforce Development Update
16:45	Q&A
16:50	 Dr Jennifer Hollands Government and Academic Liaison, Cell Therapies Pty Ltd, Melbourne, Australia Title: ISCT ANZ Workforce Development Subcommittee
16:55	Q&A
17:10	Close
18:30 – 19:00	Conference Dinner at Fraser's restaurant, Kings Park



Trusted CRISPR Nucleic Acids from Research to GMP

GenScript offers multiple non-viral DNA payload options for high-efficiency HDR gene knock-in including GenExact ssDNA, GenWand linear closed-end dsDNA, minimized circular plasmid GenCircle dsDNA, and conventional plasmids.

cGMP Production With NO Delay!

103

Clinical Grade Batches
Delivered Through July 2023

30

IND Filing
Projects Supported

6

Projects Received
NMPA IND Approval



Precision and Non-viral Solution for CRISPR-based T Cell Engineering

Date: August 18, 2023

Time: 14:00

Speaker: Dr Lumeng Ye, Director of Novel Therapeutic Materials, GenScript

Visit us at ISCT ANZ
for your chance to
win a model of
the CliniMACS
Prodigy®.



© copyright 2023

Activate your points of influence in cell expansion and fill-finish

Don't miss the opportunity to explore your key points of influence — those crucial process points where you can **minimize variability** and **enhance the consistency** of your cell product.

Benefit from our 40+ years of experience in cell collection and processing:

- See the benefits of automation with the flexible, scalable Quantum Flex Cell Expansion System — Where Cells Thrive
- Learn how the functionally closed Finia® Fill and Finish System can reduce variability and help optimize the crucial final steps of your process

Visit us at Booth 7.

©2023 Terumo BCT, Inc. | CG-QUAN-00149

TERUMO BLOOD AND CELL
TECHNOLOGIES

SGS Biosafety Solutions

Health Inspired, Quality Driven.

Our solutions

Our Center of Excellence for biosafety based in Glasgow provides:

- Electron microscopy
- GMP Sanger sequencing
- Viral vaccines Adventitious agents and species specific viruses
- Replication of competent vectors
- Retrovirus
- Process impurities
- Genetic stability
- Other microbial contaminants

Supporting a variety of molecules

Our team of experts can support manufacturers of:

- Monoclonal antibodies
- Recombinant proteins
- Viral vaccines
- Cell therapies
- Gene therapies

Contact us

To discuss your biosafety requirements, contact us today.

+44 141 952 0022
healthscience@sgs.com
sgs.com/services/biosafety
sgs.com/linkedin

"Most notably, the Biosafety Center of Excellence in Glasgow has participated in the batch-testing and release of over 3 billion doses of COVID-19 vaccine, helping to increase vaccine access and bring the global population out of the pandemic."

Archie Lovatt
Site Manager & Scientific Director at SGS

WHEN YOU NEED TO BE SURE 

08:00 -
08:30

DAY 3, August 18, 2023

Registrations continue

Session 10: Cell Therapy Clinical Trials

Chairs: A/Prof Emily Blyth & Dr Tessa Gargett



8:30



A/Prof Matt Frank

Division of Blood and Marrow Transplantation and Cellular Therapy
Stanford University, CA, USA

Title: CD22 CAR T cell Therapy Mediates High Durable Remission Rates in Adults with Large B-cell Lymphoma Who Have Relapsed After CD19 CAR T cell Therapy

08:55

Q&A

09:00



Dr Gaurav Sutrave

Westmead Institute for Medical Research
Westmead Hospital, Sydney, Australia

Title: Pathogen specific T cells - past, present and future

09:25

Q&A

09:30

Oral Abstract Presentation

Dr Tessa Gargett

Translational Oncology Lab, Centre for Cancer Biology, University of South Australia and SA Pathology; Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, Australia

Title: GD2-CAR-T therapy: Phase 1 clinical trials for aggressive primary brain tumours

09:42

Q&A

09:45

Oral Abstract Presentation

Dr David Morrison

Centre for Implant Technology and Retrieval Analysis, Health Technology Management Unit, East Metropolitan Health Service, Royal Perth Hospital, Perth, Australia

Title: Cranial Bone Reconstruction using Tissue Engineered Scaffold-Stem Cell Constructs

09:57

Q&A

Morning break sponsored by Cell Therapies

10:00

A/Prof Jane Oliaro

Chief Scientist for the Centre of Excellence in Cellular Immunotherapy
Translation Laboratory at the Peter MacCallum Cancer Centre, Melbourne

Title: The Centre of Excellence in Cellular Immunotherapy at the Peter Mac

cell therapies



Session 11: Cell Therapies in Clinical Practice

Chairs: A/Prof Emily Blyth & Dr Duncan Purtill



10:20	 <p>A/Prof Matt Frank Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University, USA</p> <p>Title: Circulating tumor DNA as an Adjunct to CAR T Cell Therapy: Predicting Outcomes and Identifying Resistance Mechanisms</p>
10:45	Q&A
10:50	 <p>A/Prof Glen Kennedy Executive Director, Cancer Care Services, Acting Executive Director, Clinical Services, MNHHS, Co-Chair Queensland Cancer Clinical Network Royal Brisbane and Women's Hospital, Brisbane, Australia</p> <p>Title: A place for place-of-care CAR T-cell therapy</p>
11:15	Q&A
11:20	<p><i>Oral Abstract Presentation</i></p> <p>Dr Mark Dowling Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre; University of Melbourne, Melbourne, Australia</p> <p>Title: Real-world Australian outcomes with CAR T-cell therapy for aggressive lymphoma</p>
11:33	Q&A
11:35	<p><i>Oral Abstract Presentation</i></p> <p>Deekshitha Dhulipati Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia</p> <p>Title: Third-party partially HLA matched fungus-specific T-cells can lead to clearance of invasive fungal infections post-allogeneic bone marrow transplant</p>
11:48	Q&A
11:50 - 12:50	<p>Corporate Lunch Session</p> <p>Title: Unifying synergies: End-to-end solution for Cell and Gene Therapy delivery</p> <div>    </div> <div>    </div> <p>Marina Rajič, CEO Julie Jones, CEO Alexandra Galbon, Head Ops.</p>

Session 12: ISCT ANZ-ISCT ASIA Joint Session

Chairs: A/Prof Zlatibor Veličković and Dr Janet Macpherson



12:50	 <p>Prof William Hwang Chief Executive Officer, National Cancer Centre Singapore, Singapore</p> <p>Title: Cell Therapy in Singapore – Lessons Learned from Our Little Island Gateway Between East and West</p>
13:15	Q&A
13:20	 <p>Dr Janet Macpherson Cytiva, Sydney, Australia</p> <p>Title: Regulatory roadmap in APAC: report from the ISCT APAC industry Committee</p>
13:40	Q&A
13:45	<p>Oral Abstract Presentation</p> <p>Dr Hamid Reza Bidkhor Amnion Biology Research Group, Hudson Institute of Medical Research, Melbourne, Australia; Stem Cells and Regenerative Medicine Department, Academic Center for Education, Culture and Research (ACECR)-Khorasan Razavi, Mashhad, Iran</p> <p>Title: Regulatory Inconsistencies of the Cell and Gene Therapy (CGT) Sector in Asia and the Pacific Region: Time for Harmonization</p>
13:57	Q&A
14:00	<p>Afternoon break sponsored by Genscript</p> <p>Dr Lumeng Ye Director of Novel Therapeutic Materials Genscript</p> <p>Title: Precision and Non-viral Solution for CRISPR-based T Cell Engineering</p>  
Session 13: The great debate	
<p>Chair: Dr Janet Macpherson and Dr Dawn Driscoll</p>  	
14:20-15:20	Panel discussion
15:20	ISCT ANZ 2024 announcement Awards and meeting close.

ISCT ANZ would like to thank our Sponsors
for their support of this regional meeting



Networking event



GOVERNMENT OF
WESTERN AUSTRALIA

Plenary

ThermoFisher
S C I E N T I F I C

Corporate Lunch Sessions

 **BioViros**

 **BioValeo**

BioOra

 **GenScript**
PROBIO

 **Rapidmicro**
biosystems®

Session Sponsors



Exhibitors



Morning and Afternoon Tea




GILEAD

cell therapies



Technologist Award



THERAPEUTIC
INNOVATION
— AUSTRALIA —